European Journal of Clinical Pharmacology 1987-01-01

Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.

C J Richardson, K L Blocka, S G Ross, R K Verbeeck

Index: Eur. J. Clin. Pharmacol. 32(1) , 89-91, (1987)

Full Text: HTML

Abstract

Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5'-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).


Related Compounds

Related Articles:

[The binding of oxicam derivatives to human serum albumin].

1988-08-01

[Arzneimittelforschung 38(8) , 1089-92, (1988)]

High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma and urine.

[J. Chromatogr. A. 382 , 382-8, (1986)]

Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography.

[J. Chromatogr. A. 576(1) , 121-8, (1992)]

Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5'-hydroxypiroxicam in human plasma and urine.

1995-11-03

[J. Chromatogr. B, Biomed. Appl. 673(1) , 142-6, (1995)]

Simultaneous determination of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma by derivative spectrophotometry.

1998-08-01

[Analyst 123(8) , 1749-52, (1998)]

More Articles...